3D Placental Volume in Placenta Accreta

NCT ID: NCT06755047

Last Updated: 2025-01-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

38 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-12-31

Study Completion Date

2025-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Placenta Accreta spectrum is a major obstetric disease nowadays. Different methods are used for antenatal diagnosis. In our study, investigators are aiming to compare 2 common ways for diagnosis, i.e; 3D Ultrasound and 2D with color Doppler.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The word placenta accreta spectrum disorders (PASD) implies an atypical implantation of the placenta into the uterine wall and has been used to express placenta accreta, increta and percreta. Placenta accreta is a placenta where the placental villi sick on directly to the myometrium. Placenta increta is a placenta where the placental villi attack into the myometrium and placenta percreta is a placenta where the villi invade through the myometrium and into serosa. No antenatal diagnostic method gives the clinician 100% assurance of either ruling in or ruling out the existence of placenta accreta. The definitive diagnosis of placental accreta spectrum is frequently ended postpartum on hysterectomy specimens when an area of accretion shows chorionic villi which make direct contact with the myometrium and absence of deciduae. Antenatal ultrasound is the method of choice used to establish the diagnosis and direct clinical management.The combined use of power Doppler with three dimensional (3D) ultrasound provides the possibility of quantifying moving blood within a volume of interest. Three indices are calculated, namely vascularization index (VI), flow index and vascularization flow index

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Placenta Accreta

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

3D Ultrasound

3D ultrasound placental volume, vascularization index, flow index and VF index

3D Ultrasound

Intervention Type RADIATION

3D placental volume and vascular indices

2D ultrasound

lacunar vascular flow, abnormal utero-placental interference, myometrial thinning (\>1mm), absence of the retroplacental myometrium, interruptions or irregularities at the level of the utero-vesical interference, lower uterine segment hypervascularity

2D ultrasound

Intervention Type RADIATION

2D placental criteria of invasion and color Doppler

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

3D Ultrasound

3D placental volume and vascular indices

Intervention Type RADIATION

2D ultrasound

2D placental criteria of invasion and color Doppler

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* pregnant women with placenta previa

Exclusion Criteria

* congenital anomalies of placenta Placental separation Uterine anomalies
Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assiut University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mohamed Gamal M.fekry

Lecturer obstetric and gynecology, Specialist Urogynecology

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Women's Health Hospital

Asyut, , Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mohamed Fekry, PhD

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mohamed Fekry, Lecturer

Role: primary

0882312388

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

3D

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Management of Placenta Accreta Spectrum
NCT04609527 UNKNOWN PHASE2/PHASE3